

A randomised trial of a community pharmacist-initiated screening and intervention program for osteoporosis: the OsteoPharm Study

Submission date 04/11/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 26/01/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 05/11/2008	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Study website

<http://www.epicore.ualberta.ca/>

Contact information

Type(s)

Scientific

Contact name

Dr Nese Yuksel

Contact details

Faculty of Pharmacy and Pharmaceutical Sciences
University of Alberta
3126 Dentistry/Pharmacy Center
Edmonton
Canada
T6R 2N6
+1 780 492 4442
nyuksel@pharmacy.ualberta.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

186

Study information

Scientific Title

Acronym

OsteoPharm

Study objectives

A community pharmacist-initiated multifaceted intervention will help increase the diagnosis and treatment of osteoporosis in patients at a high risk for fracture.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the University of Alberta, Health Research Ethics Board-A on the 14th June 2005.

Study design

Randomised, controlled multi-site trial with blinded ascertainment of outcomes

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Quality of life

Participant information sheet

Health condition(s) or problem(s) studied

Osteoporosis

Interventions

Intervention group:

Multifaceted interventions that consist of the following:

1. Screening by community pharmacists

2. Educational session on osteoporosis
3. Quantitative ultrasound (QUS) measurements
4. Referral to the primary care physician

Control group:

Usual care, defined as provision of generic pamphlet on osteoporosis.

Please note that as of 15/01/2008 the anticipated end date of this trial was extended to 30/09/2007. The previous end date of this trial was 01/10/2006.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Composite endpoint of the performance of a bone mineral density test or a new prescription for an osteoporosis medication within four months of study entry.

Secondary outcome measures

1. Each component of the primary outcome
2. Use of calcium and vitamin D supplements
3. Patients osteoporosis related knowledge using the Facts on Osteoporosis Quiz, (FoOQ)
4. Changes in generic health status (RAND-12)
5. Osteoporosis specific quality of life

Overall study start date

16/11/2005

Completion date

30/09/2007

Eligibility

Key inclusion criteria

Males or females who are:

1. Over the age of 50
2. Considered to be at a high risk for osteoporosis and fractures as defined by the Osteoporosis Society of Canada Clinical Practice guidelines and as defined specifically for the purposes of this study, i.e., are over the age of 65 years or between 50 - 64 years of age with any one of the following:
 - 2.1. Family history of osteoporosis
 - 2.2. Previous fragility fracture
 - 2.3. Systemic steroids
 - 2.4. Early menopause (for women)
3. Live in the Capital Health Region (Edmonton Region)

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

250

Key exclusion criteria

1. Are unable or unwilling to provide informed consent
2. Are on current prescription treatment for osteoporosis
3. Have had a dual energy x-ray absorptiometry (DEXA) scan performed in the past two years
4. Are non-English speaking

Date of first enrolment

16/11/2005

Date of final enrolment

30/09/2007

Locations**Countries of recruitment**

Canada

Study participating centre

Faculty of Pharmacy and Pharmaceutical Sciences

Edmonton

Canada

T6R 2N6

Sponsor information**Organisation**

University of Alberta (Canada)

Sponsor details

Faculty of Pharmacy and Pharmaceutical Sciences

3126 Dentistry/Pharmacy Center

Edmonton

Canada

T6R 2N6

+1 780 492 3362

info@pharmacy.ualberta.ca

Sponsor type

University/education

Website

<http://www.pharmacy.ualberta.ca/>

ROR

<https://ror.org/0160cpw27>

Funder(s)

Funder type

Charity

Funder Name

Institute of Health Economics (IHE) (Canada) (account number: 186)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	01/03/2006		Yes	No